Tonix is a clinical-stage biopharmaceutical company with a portfolio composed of CNS, rare disease, immunology and infectious disease product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Our lead CNS candidate is in mid-Phase 3 development for the management of fibromyalgia with interim data expected in 2Q'23. We also expect to initiate three Ph 2 studies in 1Q'23. Our Immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer. Lastly, Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):